研究单位：[1]Hoffmann-La Roche[2]Scheie Eye Institute,Philadelphia,Pennsylvania,United States,19104[3]Toronto Retina Institute,Toronto,Ontario,Canada,M3C 0G9[4]Peking Union Medical College Hospital,Beijing City,China,100032[5]Peking University Third Hospital,Beijing,China,100191[6]Beijing Hospital of Ministry of Health,Beijing,China,100730[7]Beijing Tongren Hospital, Capital Medical University,Beijing,China,100730[8]Xi'an Fourth Hospital,Xi'an City,China,710004[9]Chung-Ang University Hospital,Seoul,Korea, Republic of,06973
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
